ZURICH (Reuters) - Swiss medical device maker Synthes said on Monday that it could no longer sell or promote the use of its TFN products to treat intertrochanteric fractures in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback